Trial Profile
A Randomized, Multicenter, Double-Blind, Multinational, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) With Squamous Histology
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Sep 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 15 Jun 2018 Status changed from active, no longer recruiting to completed.
- 31 May 2018 This study has been completed in Germany. (End date: 2018-05-03)
- 25 May 2018 This study has been completed in Hungary. (End date: 2018-05-03)